106 related articles for article (PubMed ID: 11414524)
1. Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia.
Huang YC; Kao HT; Lin TY; Kuo AJ
Am J Perinatol; 2001 May; 18(3):141-6. PubMed ID: 11414524
[TBL] [Abstract][Full Text] [Related]
2. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
3. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan.
Chen TC; Chen YH; Tsai JJ; Peng CF; Lu PL; Chang K; Hsieh HC; Chen TP
J Microbiol Immunol Infect; 2005 Jun; 38(3):200-10. PubMed ID: 15986071
[TBL] [Abstract][Full Text] [Related]
4. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
5. Correlation between CLSI, EUCAST and Etest methodologies for amphotericin B and fluconazole antifungal susceptibility testing of Candida spp. clinical isolates.
Claudino AL; Peixoto RF; Melhem MS; Szeszs MW; Lyon JP; Chavasco JK; Franco MC
Pharmazie; 2008 Apr; 63(4):286-9. PubMed ID: 18468388
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
Favel A; Michel-Nguyen A; Datry A; Challier S; Leclerc F; Chastin C; Fallague K; Regli P
J Antimicrob Chemother; 2004 Mar; 53(3):526-9. PubMed ID: 14963064
[TBL] [Abstract][Full Text] [Related]
7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
8. [Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing].
Yamane N; Igari J
Rinsho Byori; 1997 Feb; 45(2):190-9. PubMed ID: 9121005
[TBL] [Abstract][Full Text] [Related]
9. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
11. [Biofilm production and antifungal susceptibility patterns of Candida species].
Yücesoy M; Karaman M
Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.
Wenisch C; Moore CB; Krause R; Presterl E; Pichna P; Denning DW
J Clin Microbiol; 2001 Jul; 39(7):2458-62. PubMed ID: 11427554
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.
Rex JH; Pfaller MA; Barry AL; Nelson PW; Webb CD
Antimicrob Agents Chemother; 1995 Jan; 39(1):40-4. PubMed ID: 7695326
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
16. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].
Durán MT; Velasco D; Canle D; Moure R; Villanueva R
Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):488-92. PubMed ID: 14572381
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome.
Park BJ; Arthington-Skaggs BA; Hajjeh RA; Iqbal N; Ciblak MA; Lee-Yang W; Hairston MD; Phelan M; Plikaytis BD; Sofair AN; Harrison LH; Fridkin SK; Warnock DW
Antimicrob Agents Chemother; 2006 Apr; 50(4):1287-92. PubMed ID: 16569842
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
20. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
Cheng MF; Yu KW; Tang RB; Fan YH; Yang YL; Hsieh KS; Ho M; Lo HJ
Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
